Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 13, 2024 (Events reported December 13–15, 2024)
Context: The filing details a significant corporate restructuring involving the acquisition of intellectual property, the creation of a new wholly-owned subsidiary ("Mango & Peaches Corp."), and a major amendment to the CEO's employment agreement resulting in a shift in control of the company's core assets.
Key Financial Metrics and Transactions
This filing does not contain standard financial statements (revenue, profit, cash flow). Key financial terms of the reported transactions include:
- Patent Acquisition Cost: 515,000 shares of restricted common stock issued to Greenfield Investments, Ltd.
- Future Royalty Obligation: 10% of gross worldwide sales of products utilizing the acquired patents, payable annually starting December 13, 2025.
- CEO Compensation (Amended):
- Base Salary: Increased to $360,000 per year.
- Expense Allowance: $7,500 per month for office and overhead costs.
- Performance Bonus: Up to $10,000,000 cash bonus (convertible to subsidiary stock at $0.50/share) based on milestones.
- Severance: Increased to 3x annual base salary plus targeted bonus upon termination without cause or for good reason.
- Debt Transfer: A $150,000 promissory note previously held by the CEO's entity (Cohen Enterprises) was sold to Mill End Capital Ltd. for $150,000.
Material Changes Versus Prior Period
- Corporate Structure: The Company formed "Mango & Peaches Corp." and contributed substantially all assets (including 98% of MangoRx Mexico and 100% of MangoRx UK) to this new subsidiary effective December 15, 2024.
- Intellectual Property: Acquired patents related to nutraceutical compositions using fungal compounds derived from mushrooms.
- Control and Governance: CEO Jacob D. Cohen received 1,700,000 shares of Mango & Peaches common stock (25.4%) and 100 shares of Series A Preferred Stock. The Preferred Stock grants 51% of the total vote on all shareholder matters, giving Cohen majority control over the subsidiary holding the Company's core assets.
- Executive Terms: CEO employment term extended to December 1, 2027, with expanded duties to include CEO of the new subsidiary.
Guidance, Outlook, Risks, and Contingencies
- Strategic Outlook: The Company intends to commercialize the acquired patents for customized health supplements. The restructuring aims to segregate operations and liabilities.
- Shareholder Ratification: The Company plans to seek shareholder ratification for the terms of the CEO's employment agreement regarding the issuance of Mango & Peaches shares at the next shareholder meeting.
- Risks and Contingencies:
- Bonus Vesting: There is no assurance that Mango & Peaches will reach the milestones required for the CEO's $10 million bonus.
- Control Concentration: If the CEO converts the full bonus into stock, he could own up to 92.8% of the subsidiary's voting stock, significantly concentrating control.
- Grant Back License: The seller (Greenfield) retains a co-exclusive license to use the patents, subject to a 10% royalty.
- Right of First Refusal: Greenfield has a right of first refusal to match offers to purchase the patents until December 13, 2027.
Investor Verification Checklist
- Verify the exact number of outstanding shares of Mangoceuticals, Inc. to assess the dilution impact of the 515,000 shares issued for the patents.
- Review the specific milestones in Exhibit B of the Amended and Restated Employment Agreement required to trigger the $10 million CEO bonus.
- Confirm the final designation terms of the Mango & Peaches Series A Preferred Stock once filed.
- Monitor the upcoming shareholder meeting for the ratification vote on the CEO's compensation and equity issuance.
- Assess the financial impact of the 10% royalty obligation on future gross sales of products utilizing the new patents.